HGH Injections For Sale

Aging is a part of life that we can't do anything about, but we can slow it down or speed it up depending on our lifestyle choices and health habits. In addition to prematurely aging, certain health issues can arise causing the process to accelerate and Eat This, Not That! Health spoke with experts who share signs you're aging faster than you should that you need to be aware of. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Dr. Tomi Mitchell, a Board-Certified Family Physician with Holistic Wellness Strategies shares, "I have yet to meet an adult who has told me they want to age quickly. The fact is, many people start to become acutely aware of their age after they hit 30. They begin to see the first signs of wrinkles and gray hair and feel aches and pains in their joints. As a result, they begin to feel like they are losing their youth and vitality. For many people, this can be a very unsettling experience. They may spend more time and money on beauty products and cosmetics to hold on to their child. They may also try to change their lifestyle habits to stay healthy and fit. However, the sad truth is that there is no turning back the clock. Aging is an inevitable part of life. However, that does not mean that we have to give in to it without a fight. By caring for our bodies and minds, we can still enjoy a high quality of life as we age. So, even though we cannot stop the aging process, we can certainly slow it down. However, there are signs that you may be aging faster than you should. You should talk to your doctor if you notice any of the following symptoms."

Lisa Richards, a nutritionist and author of the Candida Diet tells us, "For most individuals chronic pain and inflammation is not a normal part of everyday life. If you find yourself experiencing inflammation, water retention, poor sleep, and chronic pain you are likely aging faster than you should. For those without a medical diagnosis to explain these symptoms, the culprit is likely the foods you are choosing to fuel your body with. Cutting down on saturated fats, refined carbohydrates, added sugar, and other inflammatory foods can help slow down this process and lessen these side effects. Choosing to take in anti-inflammatory foods can also slow down the aging process by feeding your body antioxidant rich foods, whole grains, and healthy fats. This leads to better cellular health, gut health, immunity, and overall wellness."

"Did you know that loss of muscle mass could signify that you are aging faster than you should be?" Dr. Mitchell asks. "It's true! Muscle mass begins to decline around 30, which accelerates as we age. There are several reasons for this, including a decrease in the production of hormones such as testosterone and growth hormone and a reduction in the number of muscle cells. This process can be accelerated by poor nutrition, lack of exercise, and certain medications. However, some ways to slow down muscle loss include regular exercise, adequate protein intake, and supplementation with creatine or other nutrients. So if you're concerned about losing muscle mass, take action today to keep your body young and strong."

6254a4d1642c605c54bf1cab17d50f1e

According to Dr. Mitchell, "One of the most visible signs of aging is a change in the appearance of the skin. As we age our skin becomes thinner and less elastic, leading to wrinkles, age spots, and dryness. While this is a natural part of the aging process, it can be accelerated by environmental factors such as sun exposure and smoking. Additionally, lifestyle choices, such as a poor diet or not getting enough exercise, can contribute to premature aging. If you notice your skin showing signs of aging, it's essential to take steps to protect it from further damage. This includes sunscreen outdoors, quitting smoking, and eating a healthy diet. These steps will help you keep your skin looking its best for years."

Dr. Mitchell reminds us, "As we age, our bodies go through a lot of changes. One of the most noticeable changes is the way our bones change. Over time, our bones become weaker and more brittle. This is a natural part of the aging process, but it can signify that we are aging faster than we should be. Our bones are constantly breaking down and rebuilding themselves, but as we age, the rate at which they break down begins to exceed the rate at which they rebuild themselves. This can lead to decreased bone density and an increased risk of fractures. Several factors can contribute to this process, including a lack of exercise, a poor diet, and certain medical conditions. If you are concerned about your bone health, speak to your doctor about ways to slow down the aging process."

"When it comes to hair loss, there can be many different causes," Dr. Mitchell states. "However, one potential reason is accelerated aging. Hair loss is a normal part of the aging process, as hair follicles gradually produce more delicate and weaker strands of hair. However, losing a large amount of hair could signify that you are aging faster than you should be. Several possible reasons include hormonal imbalances, vitamin deficiencies, and stress. If you are concerned about accelerated aging, you must consult a doctor or dermatologist. In addition, they will be able to assess your case and provide guidance on how to proceed."

Dr. Mitchell states, "There's no getting around it: as we get older, our bodies change. We don't have the same energy levels we did when we were young, and we start to see the effects of time in the form of wrinkles and gray hair. But did you know that insomnia is one of the earliest signs of aging? That's right: if you're having trouble sleeping, it could signify that you are aging faster than you should be. Several factors can contribute to insomnia, but as we age, our bodies produce fewer hormones that help us sleep soundly. In addition, many medications that are commonly prescribed to seniors can have side effects that make it difficult to fall asleep or stay asleep through the night. And if that weren't enough, aging also increases our risk for medical conditions like Alzheimer's disease and Parkinson's disease, which can cause sleep problems. If you're having trouble sleeping, you should talk to your doctor. There are treatments available that can help you get the rest you need, and by addressing your insomnia, you may be able to slow down the aging process. So don't wait: if you're not getting enough shut-eye, make an appointment with your doctor today.

Dr. Mitchell says this "doesn't constitute medical advice and by no means are these answers meant to be comprehensive. Rather, it's to encourage discussions about health choices."

Read the rest here:

6 Signs You're Aging Faster Than You Should Eat This Not That - Eat This, Not That

The dynamics of the complicated urinary tract infection market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world and rising cases of complicated urinary tract infection. Leading companies like Allecra Therapeutics, Venatorx Pharmaceuticals, Wockhardt, and others are developing drugs for complicated urinary tract infection treatment.

LAS VEGAS, Sept. 12, 2022 /PRNewswire/ --DelveInsight's Complicated Urinary Tract Infections Market Insights report includes a comprehensive understanding of current treatment practices, complicated urinary tract infections emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

Key Takeaways from the Complicated Urinary Tract Infections Market Report

Discover which therapies are expected to grab major complicated urinary tract infections market share @Complicated Urinary Tract Infections Market Report

Complicated Urinary Tract Infections Overview

Urinary tract infections (UTIs) are among the most common bacterial infections. Clinically, they can manifest in various ways, ranging from relatively benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis, and severe urosepsis. cUTI is a multifaceted entity with numerous forms. Infection from microorganisms is among the major complicated urinary tract infections causes.

Complicated urinary tract infection symptoms such as increased urinary frequency, urgency, hematuria, dysuria, suprapubic or flank discomfort are the most important clinical criteria for the initial complicated urinary tract infection diagnosis. Furthermore, there must be a suitable clinical scenario in which the most likely cause of these complicated urinary tract infection symptoms is a urogenital tract infection.

The complicated urinary tract infections treatment goals are to eliminate the infection, avoid complications, and provide symptomatic relief. Early complicated urinary tract infection treatment is recommended to reduce the risk of developing pyelonephritis.

Complicated Urinary Tract Infections Epidemiology Segmentation

As per DelveInsight, there were approximately 8 million complicated urinary tract infections diagnosed incident casesin the 7MM in 2021.

Among the 7MM, the US had recorded the highest diagnosed incidence of complicated urinary tract infectionsin 2021.

The complicated urinary tract infections market reportproffers epidemiological analysis for the study period 20192032 in the 7MM segmented into:

Download the report to understand which factors are driving complicated urinary tract infections epidemiology trends @Complicated Urinary Tract Infections Epidemiological Insights

Complicated Urinary Tract Infections Treatment Market

Complicated UTIs are treated with broader antimicrobial coverage and may require intravenous antibiotics depending on severity. For difficult lower UTIs, broad-spectrum antibiotic therapy should be used for 714 days and curable underlying causes should be treated. Recurrent UTIs are common in women, and antibiotic prophylaxis may be recommended. Catheter-associated urinary tract infection (CAUTI) is one of the most common infections associated with healthcare, and it is treated with catheter removal or replacement as well as antibiotic medication. CAUTIs are frequently caused by resistant bacteria. Pregnant women should be tested and treated for UTIs and asymptomatic bacteriuria, respectively.

Moreover, Avycaz was approved in the United States in February 2015 for the treatment of adult patients with complex urinary tract infections (cUTI), including pyelonephritis, caused by identified susceptible bacteria such as certain Enterobacteriaceae and Pseudomonas aeruginosa. It was approved in Europe in June 2016. The company expanded its label for pediatric patients in the US market in March 2019 and in Europe in November 2020. Allergan and Abbvie have US rights to the drug's development, while Pfizer has market rights outside of the US. The only drugs approved for adult and pediatric patient pools are Zerbaxa and Avycaz. Other drugs approved by the FDA and EMA for complicated urinary tract infection treatment include Recarbrio (Merck), Fetroja (Shionogi), Vabomere (Melinta therapeutics), and Zemdri (Cipla therapeutics).

To know more about complicated urinary tract infections treatment options, visit @New Treatment forComplicated Urinary Tract Infections

Complicated Urinary Tract Infections Pipeline Therapies and Key Companies

Learn more about the complicated urinary tract infectionstherapies in clinical trials @Drugs forComplicated Urinary Tract Infections Treatment

Complicated Urinary Tract Infections Market Dynamics

With increasing multidrug resistance and antibiotic overuse, the prevalence of cUTIs is expected to rise in the future, propelling the growth of the complicated urinary tract infections market. Furthermore, research and development of novel classes of antibiotics for cUTI is expected to aid complicated urinary tract infections market growth.

Moreover, antibiotics are in high demand as they are the only treatment for cUTIs and UTIs. There is currently no approved drug for oral use, so the first-ever FDA approval for oral drugs will provide a competitive advantage in the complicated urinary tract infections market. Furthermore, increased mergers/acquisitions and collaborations between companies to develop safe and effective drugs will accelerate complicated urinary tract infections market growth.

However, inadequate treatment of complicated urinary tract infections increases healthcare costs, exposes patients to potential side effects, and increases antibiotic resistance, thus impeding the growth of the complicated urinary tract infections market.

Moreover, variability in study participants, a small sample size, a lack of blinding or placebo control, unpredictability in follow-up, and the exclusion of patients with resistant isolates are all likely to impede clinical trial study evaluation in the complicated urinary tract infections market.

As the clinical trial of an antibiotic differs from other therapeutic drugs in terms of clinical approval approach, such as clinical trial design, interpretation, and analysis, complex regulatory requirements are expected to hinder the growth of the complicated urinary tract infections market.

Furthermore, conflicting guidelines on uncomplicated urinary tract infections issued by various organizations cause confusion among providers that will further impact the growth of the complicated urinary tract infections market.

Scope of the Complicated Urinary Tract InfectionsMarket Report

Discover more about drugs for complicated urinary tract infectionsin development @Complicated Urinary Tract Infections Clinical Trials

Table of Contents

1.

Complicated Urinary Tract Infections Market Key Insights

2.

Complicated Urinary Tract Infections Market Report Introduction

3.

Complicated Urinary Tract Infections Market Overview at a Glance

4.

Complicated Urinary Tract Infections Market Executive Summary

5.

Disease Background and Overview

6.

Complicated Urinary Tract Infections Treatment and Management

7.

Complicated Urinary Tract Infections Epidemiology and Patient Population

8.

Patient Journey

9.

Complicated Urinary Tract Infections Marketed Drugs

10.

Complicated Urinary Tract Infections Emerging Drugs

11.

Seven Major Complicated Urinary Tract Infections Market Analysis

12.

Complicated Urinary Tract Infections Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Complicated Urinary Tract Infections Market Drivers

16.

Complicated Urinary Tract Infections Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Get in touch with our business executive@Healthcare Due Diligence Services

Related Reports

Complicated Urinary Tract Infections Epidemiology Forecast

Complicated Urinary Tract InfectionsEpidemiology Forecast 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the complicated urinary tract infectionsepidemiology trends.

Complicated Urinary Tract Infections Pipeline

Complicated Urinary Tract InfectionsPipeline Insight 2022report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key complicated urinary tract infections companies, including Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, among others.

Uncomplicated Urinary Tract Infections Pipeline

Uncomplicated Urinary Tract InfectionsPipeline Insight 2022report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key uncomplicated urinary tract infections companies, including Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, among others.

Uncomplicated Urinary Tract Infections Market

Uncomplicated Urinary Tract InfectionsMarket Insights, Epidemiology, and Market Forecast 2032report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key uncomplicated urinary tract infectionscompanies, including Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, among others.

Uncomplicated Urinary Tract Infections Epidemiology

Uncomplicated Urinary Tract InfectionsEpidemiology Forecast 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the uncomplicated urinary tract infectionsepidemiology trends.

Other Trending Reports

Diagnostic Imaging Equipment Market|Invasive Candidiasis Market| Sialidosis Market| Filgrastim Biosimilar Insight| Pain Management Devices Market| Primordial Dwarfism Market| Non-cystic Fibrosis Bronchiectasis Market| Microsatellite Stable Colorectal Cancer Market| Cystinuria Market| Deep Vein Thrombosis Market| Acquired Immunodeficiency Syndrome Market| Gene and Cell Therapies in Rare Disorder Market| Pediatric Growth Hormone Deficiency (PGHD) Market|Pain Management Devices Market| Diagnostic Imaging Equipment Market| Ischemic Stroke Market| Paget's Disease Market| Resorbable Vascular Scaffold Market| RosaiDorfman disease (RDD) Market| Salivary Gland Infection Market| Sandhoff Disease Market| Scedosporium Infection Market| Structural Heart Devices Market| Vascular Graft Devices Market| Vascular Stents Market| Vein Illumination Devices Market| Ventricular Assist Devices (VAD) Market| Adrenocortical Carcinoma Market| Cystinuria Market| Myopia Treatment Devices Market| Urology Ultrasounds Devices Market| Sly Syndrome Market| Human Papillomavirus-Positive Oropharyngeal| Cancer Market| Tuberculosis Market| Plasmodium Vivax Malaria Market| Oncolytic Virus Cancer Therapy Pipeline| Facial Lines Market| Rosacea Market| Polycystic Kidney Disease Market| Oropharyngeal Cancer Market| NPC Market| Immune Thrombocytopenia Market

AboutDelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.

Connect with us onLinkedIn|Facebook|Twitter

Contact Us:Shruti Thakur [emailprotected]+1(919)321-6187www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

Read more:

Complicated Urinary Tract Infections Market to Witness Growth at a CAGR of 5.9% by 2032 | DelveInsight - PR Newswire

Wilmington, Delaware, United States, Transparency Market Research Inc. Triple-negative breast cancer (TNBC) doesnt have estrogen or progesterone receptors and also doesnt make too much of the HER2 protein. Because the cancer cells lack these proteins, hormone therapy and drugs that target HER2 are not helpful, so chemotherapy (chemo) is the main systemic treatment option. And although TNBC tends to respond well to initial chemo, it tends to come back (recur) more frequently than other breast cancers.

Read Report Overview https://www.transparencymarketresearch.com/triple-negative-breast-cancer-treatment-market.html

If the early-stage TNBC tumor is small enough to be removed by surgery, then breast-conserving surgery or a mastectomy with a check of the lymph nodes may be done. In certain cases, such as with a large tumor or if the lymph nodes are found to have cancer, radiation may follow surgery.

Because hormone therapy and HER2 drugs are not good options for women with TNBC, chemotherapy is the main systemic option. It might be given before surgery (neoadjuvant chemotherapy) to shrink a large tumor. If cancer is still found after neoadjuvant chemo has been given, the doctor may recommend to take an oral chemo drug called capecitabine for 18 to 24 weeks. A pateint might also be given chemo after surgery (adjuvant chemotherapy) to reduce the chances of the cancer coming back.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50904

Global Triple-Negative Breast Cancer Treatment Market: Overview

The global triple-negative breast cancer treatment market is projected to witness a promising growth in the coming few years. The rising number of breast cancer cases and the advancements in the medical sector holds immense growth potential in the coming few years. The research study on the triple-negative breast cancer treatment market offers a detailed study, highlighting the key segmentation, regional outlook, and the competitive landscape.

Global Triple-Negative Breast Cancer Treatment Market: Key Trends

The rising focus of the players on the research and development activities for therapies and drugs for rare diseases is estimated to create a huge opportunity, thus supporting the growth of the market. The high number of clinical trials for the combination therapies and the increasing number of collaborations and mergers are predicted to encourage the market growth throughout the forecast period.

Request for ToC https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=50904

Furthermore, the presence of a robust pipeline of drugs in the clinical development so as to treat breast cancers is another key factor predicted to drive the global triple-negative breast cancer treatment market in the near future.

Global Triple-Negative Breast Cancer Treatment Market: Market Potential

Triple-negative breast cancer treatment is majorly treated with a combination of therapies, including radiation therapy, surgery, and chemotherapy. Several research studies have stated that hormone-receptor-negative breast cancers have responded effectively to chemotherapy in comparison with the breast cancers that are hormone-receptor-positive. The advent of new and effective treatments and the rising awareness among people concerning the lifestyle changes that are required to be made are likely to bid potential development opportunities for the key players in the forecast period.

Request for Report Methodology https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=50904

Global Triple-Negative Breast Cancer Treatment Market: Regional Outlook

Among the key regional segments, North America is projected to account for a massive share of the market in the next few years. The presence of several leading players and the availability of advanced healthcare infrastructure are expected to support market growth in the near future. Moreover, the investments by private and government organizations for research activities is expected to enhance the market growth in the coming years.

Furthermore, Asia Pacific is predicted to witness high growth, thanks to the rising contribution from India and China. In addition, the rising prevalence of triple-negative breast cancer and the increasing treatment rate are likely to augment market growth in the near future.

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=50904

Global Triple-Negative Breast Cancer Treatment Market: Competitive Analysis

The global market for triple-negative breast cancer treatment market is competitive in nature with a presence of several players operating worldwide. The key focus of the players on research and development activities, along with technological advancements in the medical sector are estimated to support the market growth in the forecast period.

In addition to this, the development of new and effective drugs and therapeutics is projected to offer growth opportunities for players in the near future. Some of the key players operating in the triple-negative breast cancer treatment market across the globe are Mylan N.V., Sanofi S.A., Celgene Corporation, F. Hoffman - La Roche Ltd., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Pfizer, Inc., and Johnson & Johnson Services, Inc.

More Trending Reports by Transparency Market Research

Medical Device Technologies Market: The global medical device technologies market is expected to reach the value of US$ 662.7 Bn by the end of 2028.

Animal Healthcare Market: The global animal healthcare market is expected to cross the value of US$ 63.2 Bn by the end of 2028.

Erectile Dysfunction Drugs Market: The global erectile dysfunction (ED) drugs market is expected to reach the value of US$ 2.5 Bn by the end of 2028.

Regulatory Affairs Outsourcing Market: The global regulatory affairs outsourcing market is expected to reach the value of US$ 17.3 Bn by the end of 2028.

Digital Health Market: The global digital health market is expected to cross the value of US$ 1.2 Trn by the end of 2028.

Equine Healthcare Market: The global equine healthcare market is expected to cross the value of US$ 972.8 Mn by the end of 2028.

Stem Cells Market: The global stem cells market is expected to reach the value of US$ 25.68 Bn by the end of 2028.

Medical Imaging Equipment Market: The global medical imaging equipment market is expected to reach the value of US$ 50.3 Bn by the end of 2028.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, providescustom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.com

Blog: https://tmrblog.com

Email: sales@transparencymarketresearch.com

Link:

Triple-Negative Breast Cancer Treatment Market to Experience Significant Growth During the Forecast Period 2026 - BioSpace

- Company to host Key Opinion Leader webinar today, September 12, at 1:30 pm CT/2:30 pm ET -

LYON, France and CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive efficacy and safety data from the first cohort of its ongoing Phase 2a study of AZP-3601 in patients with hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR), which is being held September 9-12 in Austin, TX.

During three months of treatment with AZP-3601, mean serum calcium levels were maintained within the target range and allowed for the discontinuation of oral calcium and active vitamin D supplementation in most patients. Normalization of urinary calcium was rapidly achieved in all patients, including those with hypercalciuria at baseline, together with restoration of balanced bone resorption/formation activity. AZP-3601 was well tolerated and demonstrated a favorable safety profile.

We are very pleased with the compelling results from the first patient cohort of this ongoing trial, said Mark Sumeray, M.D., chief medical officer of Amolyt Pharma. The data demonstrate that the mechanism of action of AZP-3601 translates into important potential clinical benefits for patients with hypoparathyroidism, in particular those with or at risk of developing hypercalciuria, osteopenia or osteoporosis, who represent the majority of patients with this disease. We look forward to results from Cohort 2, which will inform the design of a Phase 3 trial as we work to advance this promising therapeutic peptide through an efficient late-stage development plan.

Key findings:

The study was a three-month multi-center open-label design. Following an optimization period of up to eight weeks during which calcium and active vitamin D supplementation were adjusted to achieve baseline albumin-adjusted serum calcium (AdsCa) within the range of 7.8 to 9.0mg/dL, patients received a daily subcutaneous (sc) administration of 20g AZP-3601 for 28 days, while simultaneously reducing their calcium and active vitamin D intake. Further up-titration to a maximum dose of 60 g/d was recommended if needed to achieve AdsCa within the target range.

Thierry Abribat, Ph.D., founder and chief executive officer of Amolyt Pharma, added, With AZP-3601, our key underlying assumption is that intermittent administration of this PTH analog targeting the R0 conformation of the PTH receptor would induce a long-acting effect on serum Ca, mainly through a potent and sustained effect on Ca reabsorption in the kidney, while stimulating resumption of normal bone metabolism, thus preserving bone minerality. These data support this assumption, outlining a potentially new clinical profile, which we believe is ideally suited to address the needs of patients with hypoparathyroidism.

Oral Presentation Details:Title: Efficacy and Safety of AZP-3601, a Novel Investigational Long-Acting PTH Analog for Treatment of Hypoparathyroidism. Results From the First Cohort of a 3-Month Multi-Center Open Label Phase 2a StudyFormat: Late-breaking oral presentationDate: Monday, September 12, 2022Session time: 11:30 am-12:45 pm CT (12:30 pm-1:45 pm ET)Presentation time: 11:30 am-11:45 am CT (12:30 pm-12:45 pm ET)Author/Presenter: Istvan Takcs, M.D. (Semmelweis University, Budapest, Hungary), author and lead investigator of the study

Investor webinar:Amolyt will host a KOL webinar to discuss these Phase 2a results in more detail today, September 12, 2022, at 1:30 pm CT/2:30 pm ET. Interested parties can register for the webinar here.

About Hypoparathyroidism Hypoparathyroidism is defined by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and elevated phosphorus levels in the blood. Approximately 80% of the estimated 80,000 people in the U.S. and 110,000 in the European Union with hypoparathyroidism are women. Despite available treatments, patients experience persistent, life-altering symptoms and often develop complications and comorbidities that diminish quality of life and create segments of the patient population with specific clinical needs. Clinical manifestations of hypoparathyroidism impact many tissues and organ systems, in particular, the kidneys and bone. 17% of patients with hypoparathyroidism have osteopenia or osteoporosis and 53% are peri- or postmenopausal women with an increased risk of developing osteoporosis. Approximately 26% of patients with hypoparathyroidism have chronic kidney disease or failure, highlighting the importance of reducing urinary calcium excretion as a key treatment goal.

About AZP-3601AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism, and to limit urine calcium excretion by restoring calcium reabsorption by the kidney, with the goal of consequently preventing chronic kidney disease. In addition to its unique receptor profile, AZP-3601 is also designed to have a short half-life to potentially preserve bone integrity, an important benefit, since many patients are peri- and postmenopausal women with an increased risk of developing osteoporosis.

About Amolyt PharmaAmolyt Pharma, a clinical stage biotechnology company, is building on its teams established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes AZP-3601, a long-acting PTH analog as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.

Go here to read the rest:

Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the...

HILTON HEAD ISLANDPeople move to Hilton Head for all kinds of reasons. The beach, the golfing, the weather. Parker Wood came for the bike paths.

"Me being able to get around on a bicycle and having my independence was a big key," said Wood, 20. Because he was born before his eyes fully developed, he doesn't see perspective well enough to drive.

But he can hop on two wheels and zip the 18 miles to and from his two jobs busing tables and prepping drinks at restaurants. When Wood flips on his e-bike's pedal assist, the commute is both quicker and easier.

"My e-bike is my car," he said.

Parker Wood is seen in his reflector setting up the gadgets needed to ride his electric bike to work on Aug. 31, 2022, on Hilton Head. Wood uses his bike as his main form of transportation due to limited vision going between work and the gym routine. Andrew J. Whitaker/Staff

Not everyone is enthusiastic about sharing Hilton Head with e-bikes, which are heavier and can be faster than conventional bicycles.

But last month Town Council passed 5-1 an ordinance allowing them on the town's 64 miles of public pathways.

The one dissenting voter, Tamara Becker, told The Post and Courier the island has not figured out a way to ensure everyone's safety.

"If you don't have a solution that works, you don't put something on paper and call it a day," Becker said.

Small motorized vehicles are still not allowed on pathways.

However, for advocates the vote to allow e-bikes is not just a concession to South Carolina law, which considers"electric-assist bicycles" and "bicycles with helper motors" simply bicycles, not mopeds. Instead, enthusiasts like Wood hope the new ordinance ushers in a future in which e-bikes are a permanent part of the island's transportation ecosystem.

Parker Wood waves to a motorist while commuting to work on his electric bike on Aug. 31, 2022, on Hilton Head Island. Andrew J. Whitaker/Staff

Frank Babel, 80, is known for two things: biking and persistence.

When he retired to Hilton Head in 2004 he was appalled by its infrastructure for cycling. So he started a group called Squeaky Wheels.

"I was the guy who went to these meetings in the Town Hall and said 'You know, your maintenance is terrible. The pathways are dirty. We have no maps. How do you get across the street safely?'"

Eventually, he persuaded officials to his cause. The town invested in crosswalks, traffic signals and safety islands. It widened the pathways and added more of them.

Today a cyclist on Hilton Head can get pretty much anywhere on a paved trail that winds around neighborhoods and resorts, over wooden bridges and under tree canopies. Crashes have also gone down.

Thanks in large part to Babel and his organization, which morphed into Bike Walk Hilton Head Island, the League of American Bicyclists has three times named the island aBike Friendly Community.

Babel's success offers both an example of how the island can evolve and an explanation for why e-bikers want to come here.

"We plan (our vacations) around bike paths," said Deb Camp, 68, who'd come to Hilton Head from Florida with her husband, Warren Camp, 74. "He's enjoying it. We're getting out of the house."

Parker Wood rides down a bike path from work on Aug. 31, 2022, on Hilton Head Island. Andrew J. Whitaker/Staff

The Camps are exactly the kind of people e-bike advocates say the vehicles stand to benefit: those who wouldn't otherwise be able to ride.

"I'd gotten injured in the service and broke my back," said Warren Camp, who keeps a Vietnam Vet cap dangling from his bike frame. "Then I drove an e-bike in Fort Myers, and it changed my life forever."

Compared with a regular bike, Camp says e-bikes are more comfortable and easier to ride. He uses the pedal-assist feature "so I'm able to go twice, three times the distance without using a throttle," he said.

Camp pointed to a speedometer on the handlebar that shows how fast he's going usually around 11 mph on Hilton Head's pathways, he said.

And if he encounters walkers or slower-moving bikers on the trail?

Camp touched a lever and made a cheery ding. "Everybody likes a little bell," he said.

Jim Hall, owner of Hilton Head Electric Bicycle Co., wheels out one of the electric bikes from his shop on Aug. 31, 2022, in Hilton Head. Hall said recently electric bikes have been becoming more popular on the island as prices have been going down. Andrew J. Whitaker/Staff

The owner of Hilton Head Electric Bicycle Co., Jim Hall, said he sees a lot of folks like the Camps.

"The vast majority of (e-bike renters) were the older demographic," said Hall, who began building his fleet of e-bikes shortly after he and his wife bought the company in 2020. "Spouses that wanted to ride together, people with new hips and knees. ... We've outfitted bikes to allow folks to put their crutches on them."

The data the Halls collected from about 500 e-bike customers belied an image of buzzing swarms of young people tearing around the island; instead, "we had more people in their 80s than their 20s," Hall said.

Still, he acknowledged that some people react negatively to the sight of an e-bike. For someone used to the slender silhouette of a road bike or the easy-going attitude of a beach cruiser, e-bikes can appear like they've been injected with a growth hormone. Their tires are bigger and fatter, and the ones in Hall's shop can weigh 70 pounds.

"In fairness, people who are anti e-bike have concerns about colliding with someone on that," Hall said.

But e-bikes are not going away, at least as far as Hall can see. "There's more of them on the island every day, whether we're selling them or people are ordering them off of Amazon," he said.

The Halls do such a brisk business that they operate two separate shops now, what they call "the electric side" and "the acoustic side." The electric side makes more money.

"We've been blown away," Hall said. Ranging from about $1,000 to almost $4,000, his e-bikes both cost more and sell better.

Even he and his wife own a pair. With parking and traffic being such an issue on Hilton Head "it's a beautiful way to get around and go out," he said.

While e-bike enthusiasts can speak glowingly about their benefits for commuters, parents, people with disabilities, the environment the person responsible for dealing with collisions, the town'snew director of Public Safety, offered a more matter-of-fact perspective.

"I've been working (on Hilton Head Island) for over 30 years," said Bob Bromage. "I can assure you there have been numerous accidents involving bicycles and vehicles."

The way forward, Bromage said, is education.

On that assertion, he aligns both with the town's new ordinance, which requires anyone who rents or sells an e-bike to provide safety information, and with the national Bicycle Friendly America Program.

Amelia Neptune, who directs the program, said the organization now takes receptiveness to e-bikes into account when making Bicycle Friendly Community awards, which Hilton Head will apply for again in 2023.

"We want to see a community ... allowing e-bikes anywhere a bike would be, but coupling that with education," Neptune said.

For example, e-bike riders should know trail etiquette, how to be audible as they're passing, and why it's important to go at a reasonable speed.

Neptune pointed out that on a road with cars, bikers are at risk. On a trail with e-bikes, pedestrians are at risk. In either of those situations, education protects the most vulnerable.

In addition, town staff are looking at structural ways to enhance safety, said community planning manager Missy Luick. Those elements might include signs, rights of way, and centerline striping.

E-bikes are here already, Luick said. Insofar as the number and range of people using Hilton Head's pathways present difficulties, she said, "they're all good problems to have."

View post:

Like it or not, e-bikes on Hilton Head are here - Charleston Post Courier

DUBLIN--(BUSINESS WIRE)--The "Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.

The global biosimilars market reached a value of nearly $11,418.9 million in 2021, having grown at a compound annual growth rate (CAGR) of 34.8% since 2016. The market is expected to grow from $11,418.9 million in 2021 to $25,985.2 million in 2026 at a rate of 17.3%. The market is then expected to grow at a CAGR of 18.0% from 2026 and reach $59,555.8 million in 2031.

This report describes and explains the biosimilars market and covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.

Growth in the historic period resulted from an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration.

Factors that negatively affected growth in the historic period were regulatory changes, low healthcare access, lack of awareness on biosimilars among primary care physicians and specialists, reimbursement challenges, the coronavirus pandemic and low healthcare reimbursements.

Going forward, increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Factors that could hinder the growth of the biosimilars market in the future include high costs of drugs, high cost of drug development with threat of failure, pricing pressures from regulators and insufficient and outdated health system.

The biosimilars market is segmented by type into monoclonal antibodies, insulin, erythropoietin, granulocyte-colony stimulating factor, other hormones and others. The monoclonal antibodies market was the largest segment of the biosimilars market segmented by type, accounting for 39.6% of the total in 2021. Going forward, the erythropoietin segment is expected to be the fastest growing segment in the biosimilars market segmented by type, at a CAGR of 28.2% during 2021-2026.

The biosimilars market is also segmented by application into oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The chronic and autoimmune diseases market was the largest segment of the biosimilars market segmented by application, accounting for 45.6% of the total in 2021. Going forward, infectious diseases segment is expected to be the fastest growing segment in the biosimilars market segmented by end-user, at a CAGR of 24.8% during 2021-2026.

Western Europe was the largest region in the biosimilars market, accounting for 66.0% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the biosimilars market will be Africa and Eastern Europe where growth will be at CAGRs of 117.0% and 60.1% respectively. These will be followed by South America and Middle East where the markets are expected to grow at CAGRs of 53.854% and 53.851% respectively.

The global biosimilars market is concentrated, with a small number of large players in the market. The top ten competitors in the market made up to 76.98% of the total market in 2021. The market concentration can be attributed to the high barriers to entry in terms of high costs associated with the research and development of pegfilgrastim biosimilars and the stringent regulations set up by the regulatory authorities.

Going forward the market is expected some fragmentation with the rising number of new entrants. Amgen was the largest competitor with 21.23% of the market, followed by Pfizer with 13.37%, Novartis AG with 10.13%, Samsung Bioepis Co., Ltd. with 9.90%, Viatris with 7.37%, Biocon with 3.60%, Celltrion, Inc. with 3.24%, Coherus Biosciences with 4.17%, Elli Lilly and Company with 1.99%, and Dr. Reddy's Laboratories with 1.98%.

The top opportunities in the biosimilars market segmented by type will arise in the monoclonal antibodies segment, which will gain $8,508.0 million of global annual sales by 2026. The top opportunities in the biosimilars market segmented by application will arise in the oncology segment, which will gain $6,889.0 million of global annual sales by 2026. The biosimilars market size will gain the most in the USA at $6,677.4 million.

Market-trend-based strategies for the biosimilars market include focus on robust R&D activities for the development of effective and innovative drugs, focus on focus on M&A growth strategies, focus on establishing strategic partnerships, focus on increasing investments and focus on artificial intelligence.

Player-adopted strategies in the biosimilars market include strengthening product portfolio by new products launches, focusing on expansion strategies in different geographies and increasing research and development for new product development by collaborating with companies having same business.

To take advantage of the opportunities, the publisher recommends the biosimilars companies to launch new products, invest in robotics and artificial intelligence (AI), expand in emerging markets, scale up through merger and acquisition activity, provide competitively priced offerings, continue to participate in events and conferences, take initiatives to educate consumers, target high-growth application areas and increase strategic partnerships.

Key Topics Covered:

1. Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction and Market Characteristics

6.1. General Market Definition

6.2. Summary

6.3. Market Segmentation By Type

6.3.1. Monoclonal Antibodies

6.3.2. Insulin

6.3.3. Erythropoietin

6.3.4. Granulocyte-Colony Stimulating Factor

6.3.5. Other Hormones

6.3.6. Other Types

6.4. Market Segmentation By Application

6.4.1. Oncology

6.4.2. Chronic and Autoimmune Diseases

6.4.3. Growth Hormone Deficiency

6.4.4. Infectious Diseases

6.4.5. Other Applications

7. Major Market Trends

7.1. Robust Research & Development

7.2. Demand For Biosimilars In The Treatment Of Neutropenia

7.3. Growing Mergers And Acquisitions

7.4. Revised FDA Regulations To Facilitate Biosimilar Drug Development

7.5. Large Number Of Strategic Partnerships

7.6. Increasing Investments In Biosimilars Market

7.7. Use of Robots and AI

8. Global Market Size And Growth

8.1. Market Size

8.2. Historic Market Growth, 2016 - 2021, Value ($ Million)

8.2.1. Market Drivers 2016 - 2021

8.2.2. Market Restraints 2016 - 2021

8.3. Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)

8.3.1. Market Drivers 2021 - 2026

8.3.2. Market Restraints 2021 - 2026

9. Global Biosimilars Market Segmentation

9.1. Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

9.2. Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

10. Biosimilars Market, Regional And Country Analysis

10.1. Global Biosimilars Market, By Region, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

10.2. Global Biosimilars Market, By Country, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/7k2tzs

See the original post:

Biosimilars Global Market Opportunities and Strategies Report 2022: Long-term Forecast to 2026 & 2031 - ResearchAndMarkets.com - Business Wire

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (LUMO, Financial), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference in September.

The webcast for the presentation can also be found on the Companys website under Events & Presentations in the Investors & Media section. Please contact your H.C. Wainwright salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Sant Ventures, and UCB. Lumos Pharmas lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa MillerLumos Pharma Investor Relations512-792-5454[emailprotected]

Source: Lumos Pharma, Inc.

Read the original:

Lumos Pharma to Participate in the HC Wainwright 24th Annual Global Investment Conference - GuruFocus.com